American Society of Clinical Oncology Annual Meeting: Breast Cancer

Articles

The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.

Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

Four-Gene Signature Identified Triple-Negative Breast Cancer Subgroups

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. 

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer

A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding tumor tissue in patients with metastatic breast, lung, and prostate cancer.

‘High-Intensity’ Sequencing Detected Breast, Prostate Cancers in Blood

Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer.

Dual HER2 Blockade Superior to Single Blockade for HER2+/HR+ Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer. 

Oral SERD Promising in ER-Positive Breast Cancer With ESR1 Mutations

Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer.  

Ipatasertib ‘Modestly’ Prolongs PFS in Triple-Negative Breast Cancer

Videos

This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients

The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.

American Society of Clinical Oncology Annual Meeting: Breast Cancer | Conference